Christopher Williams, Senior Clinical Research Fellow at University of Leeds, shared a post on LinkedIn:
“Neoadjuvant chemotherapy in loc adv colon cancer
New meta-analysis from Mayo Clinic Healthcare researchers.
Includes FOxTROT, OPTICAL, PRODIGE-22 and NeoCol.
Neoadjuvant chemo vs Straight-to-surgery:
5yr OS 81.4% vs 77.8%
5yr DFS 79.2% vs 73.7%
R1 resections 4.1% vs 6.3%.”
Title: Oncological Outcomes of Neoadjuvant Chemotherapy Versus Upfront Surgery in Locally Advanced Colon Cancer: A Systematic Review, Meta-Analysis, and Sequential Analysis
Authors: Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Francesco Brucchi, Giulio Mari, Isacco Montroni, Eric J. Dozois, David W. Larson
More posts featuring Colon Cancer on OncoDaily.